Insulet Corporation (PODD) cash flow statement

Health Care Equipment · NASDAQ · Health Care

$145.34 +0.03% Close Nov 17, 2026 Live

TrendArc score 63 of 100 · Health 8.9 · Momentum 4.7 · Moat 7.2 · scored Nov 17, 2026 · How the score works

Free cash flow, fiscal year to December 31, 2025

$350 million

up 18.1% from the year before

Insulet generated $350 million of free cash flow in the fiscal year to December 2025: $569 million of cash from operations less $219 million of capital spending. That was 12.9% of revenue, against 14.3% the year before. Over the last four quarters, to September 30, 2026, it was $233 million.

Free cash flow and net income, the last 10 fiscal years

-$200M$200M$400M$600M2016201720182019202020212022202320242025-$6.20MFree cash flow $350MNet income $247M-$200M$200M$400M$600M20172019202120232025Free cash flow $350MNet income $247M

Fiscal years, each labelled by the calendar year it ended in. Every figure is in the statement below.

Where the cash wentFiscal year to December 31, 2025

  1. Cash from operations 569
  2. Capital spending -219
  3. Free cash flow 350
  4. Net share repurchases -26
  5. Debt and other -562
  6. Net change in cash -237

In millions of US dollars. Outflows are grey, not red: a buyback is not a loss. "Debt and other" closes the gap to the reported change in cash. Buying marketable securities moves cash into short-term investments; the balance sheet shows both.

Cash flow statement, the last 10 fiscal years

In millions of US dollars. Each column is a fiscal year, named by the month it ended; the first column adds up the last four quarters. Cash paid out is a negative number.
Fiscal year toLast 4 quarters
to Sep 2026
Dec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
Operating activities
Net income2474182065177123-27-29
Depreciation and amortisation90817363575528161414
Stock-based pay8263694841343629383224
Working capital and other items169-138-18210-177-1430-21227
Cash from operations509569430146119-688498364116
Investing activities
Capital spending-276-219-134-109-157-123-167-164-157-74-22
Businesses bought and sold, net000-26000006
Investments bought and sold, net0-12-7-84018197-22-134-162
Other investing-30-3000-7-5-30
Cash from investing-223-146-119-191-8314-74-185-211-178
Financing activities
Debt issued or repaid, net-708-41-27-4045126117-7293175
Shares issued less bought back-281-26202716245095116165
Dividends paid00000000000
Other financing139-8-14-17-28-30-94-18-4-3
Cash from financing-595-28-14-404160674-9305177
Exchange rate effect12-72-4-652-100
Net change in cash-23724914-117-116708100-15913515
Free cash flow
Free cash flow23335029637-38-191-83-65-122-33-6
Free cash flow margin7.3%12.9%14.3%2.2%-2.9%-17.4%-9.1%-8.8%-21.6%-7.0%-1.7%
Free cash flow per share$4.87———————-$0.56-$0.11
Free cash flow less stock-based pay287227-12-79-225-118-94-159-64-30

Shares issued less bought back is the cash from shares sold less the cash paid for shares bought back (negative when more was bought back), and includes tax withheld when employees' shares vest. Working capital and other items is cash from operations less net income, depreciation and amortisation, and stock-based pay (calculated by TrendArc). Company filings as standardised by Tiingo; calculations by TrendArc. Rebuilt nightly.

Insulet against its peers

CompanyFiscal year toFree cash flowFree cash flow margin
ResMedRMD Jun 2026$1.65B29.2%
Idexx LaboratoriesIDXX Dec 2025$1.04B24.2%
DexcomDXCM Dec 2025$1.08B23.1%
RevvityRVTY Dec 2025$509M17.8%
SterisSTE Mar 2026$983M16.6%
InsuletPODD Dec 2025$350M12.9%
GE HealthCareGEHC Dec 2025$1.50B7.3%
Baxter InternationalBAX Dec 2025$323M2.9%
Peer median17.8%

Each company's newest fiscal year; some end in other months. The peers are the stock card's peer group.

Next

Follow Insulet with a free account.

A watchlist, price alerts and saved chart layouts. No card needed.

Sign up free

No forecast, no recommendation. This page describes Insulet Corporation from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Nov 17, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.

The TrendArc score, from 0 to 100, combines three pillars measured from published data, Health (business quality over the last twelve months), Momentum (the price against its moving averages, its 52-week high and the market) and Moat (durability over five years), with the share price's long-run trend. It describes the company as it stands today. It is not a forecast or a recommendation.